We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
FDA Advisory Panel Recommends Against Approval Of Merck's NDA For Non Prescription MEVACORŪ (lovastatin) 20 Mg
Cholesterol Merck & Co., Inc. announced that the U.S. Food and Drug Administration's (FDA) joint panel of the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted against recommending approval at this time of the over-the-counter (OTC) use of MEVACORŪ (lovastatin) 20 mg to help lower LDL cholesterol which may prevent a first heart attack. "We are disappointed in today's outcome. [click link for full article]
Custom Search
